Reviva plans second Phase 3 trial after FDA feedback

Reviva Pharmaceuticals Holdings ( (RVPH) ) has shared an announcement.

At its annual meeting on December 18, 2025, Reviva Pharmaceuticals shareholders elected five directors for one-year terms, ratified Baker Tilly US as the auditor for fiscal 2025, approved executive compensation, and cleared key capital-structure measures, including raising the authorized common shares from 315 million to 515 million and authorizing the board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-20 any time before December 31, 2026; sufficient votes rendered a contingency adjournment proposal unnecessary. On December 23, 2025, the company reported that following a pre-NDA meeting, the FDA recommended a second Phase 3 trial of its schizophrenia candidate brilaroxazine to strengthen efficacy and safety data before a U.S. filing, prompting Reviva to plan the RECOVER-2 registrational study for the first half of 2026, subject to financing, a step that could extend timelines but, if successfully executed, bolster the drug’s regulatory case in a competitive CNS market and underscores the company’s reliance on additional capital to advance late-stage development.

The most recent analyst rating on (RVPH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.

Spark’s Take on RVPH Stock

According to Spark, TipRanks’ AI Analyst, RVPH is a Underperform.

Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.

To see Spark’s full report on RVPH stock, click here.

More about Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on discovering, developing and commercializing next-generation therapeutics targeting central nervous system, inflammatory and cardiometabolic diseases. Its pipeline currently centers on two in‑house discovered new chemical entities, brilaroxazine (RP5063) and RP1208, for which the company holds composition of matter patents in the United States, Europe and several other countries.

Average Trading Volume: 9,766,334

Technical Sentiment Signal: Sell

Current Market Cap: $68.91M

Find detailed analytics on RVPH stock on TipRanks’ Stock Analysis page.